At a Glance
- Tasks: Design and build innovative CRISPR-based therapeutic constructs for cancer treatment.
- Company: Exciting early-stage biotech with a focus on programmable therapeutics.
- Benefits: Competitive salary, dynamic work environment, and opportunities for growth.
- Other info: Be part of a rapidly growing company with significant impact potential.
- Why this job: Join a pioneering team and make a real difference in oncology.
- Qualifications: Experience in molecular cloning, protein engineering, and CRISPR/Cas techniques.
The predicted salary is between 66582 - 80000 £ per year.
An exciting opportunity has arisen to join a newly funded, early-stage biotechnology company developing a highly ambitious programmable therapeutics platform for oncology.
Having recently secured significant seed funding, the company is now expanding its scientific team as it progresses its platform from validation into preclinical development across multiple cancer indications.
Their technology is focused on engineering programmable therapeutic systems that can recognise disease-defining genetic features and selectively act within target cells, creating the potential to address oncology indications that remain difficult to treat through conventional therapeutic approaches.
This is a hands-on, high-throughput role at the core of the company’s platform.
You will be responsible for designing, building and iterating on novel CRISPR-based therapeutic constructs, helping to shape the candidates that move into preclinical development.
Why Join?
Join a recently seed-funded biotech at a pivotal stage of scientific and company growth Help build a novel oncology platform based on programmable, target-selective therapeutic biology Work directly on the therapeutic constructs that underpin the company’s lead programmes Apply cutting-edge molecular cloning, protein engineering and CRISPR/Cas expertise in a fast-moving environment Play a key role in expanding the platform across multiple oncology indications About the Role As Molecular Cloning
